Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes

Wong, Sandra L.; Chao, Celia; Edwards, Michael J.; Carlson, David J.; Laidley, Alison L.; Noyes, R. Dirk; McGlothin, Terre Q.; Ley, P.; Tuttle, Todd M.; Schadt, Mark E; Pennington, Robert C.; Legenza, Mary; Morgan, James D.; McMasters, Kelly M.

doi:10.1016/s0002-9610(02)01057-7

Cited by 59 publications

(35 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is in accordance with the observations of many authors who emphasis that patients with this advanced stage of the disease clearly predominate in percentage terms [2,10,18,21,22,24,25,[28][29][30]. According to certain authors, patients with stages I and II° of the disease represent more than 90% of the total.…”

Section: Stage Of Diseasesupporting

confidence: 92%

“…Similar population, microscopic and clinical characteristics, as well as immunohistochemically studied factors can be found quite often in the literature, obviously in varying frequency and intensity [1,2,15,17,18,[21][22][23][24][25][26][27][28][29][30]. However, it is important to stress that making strict comparisons between the present study group of patients and groups presented by other authors is very difficult and remains a questionable approach, since a T-MBC diagnosis itself is problematic and controversial.…”

Section: Clinicopathologic Characteristicsmentioning

confidence: 60%

“…Hang et al reported that tumours < 5 cm accounted for 92.3% [28] of the total, while Cao et al gave a figure of 97.4% [18] and Flucke et al -98.2% [17]. Meanwhile both Wang et al [29] and Vu-Nishino et al [16] reported that such tumours accounted for approximately 100% of their cases.…”

Section: Size Of Tumour In the Breastmentioning

confidence: 99%

See 2 more Smart Citations

Typical medullary breast carcinoma: clinical outcomes and treatment results

Stelmach¹,

Ryś²,

Mituś³

et al. 2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Typical medullary breast carcinoma (T-MBC) accounts for less than 1% of all malignant breast neoplasms, and immunohistochemically is characteristic of "triple-negative" breast carcinoma. The purpose of this study was to describe the clinical characteristics and treatment results for patients with T-MBC treated at a single institution, and discuss the controversial aspects of this very rare form of breast cancer. Analyses was performed in 120 patients with T-MBC who were treated between 1970 and 2005. These cases represent 1.1% of all (11 270) patients treated for breast cancer during this period. According to TNM classification, 26 patients (21.6%) were in stage I, 80 patients (66.7%) in stage II and 14 (11.7%) in stage III of clinically advanced breast cancer. Involved axillary lymph nodes occurred in just 10 (8.3%) of the patients, and in all cases metastases were observed in 1-3 lymph nodes. All the patients underwent primary surgery. Radical mastectomies were performed on 98 (81.6%) patients, while the other 22 (18.4%) underwent breast-conserving surgery (BCS). Radiotherapy was performed in 36 patients (22 after BCS and 14 after mastectomy). Patients with nodal involvement (10 patients) received adjuvant chemotherapy, and 8 patients with hormone receptor expression received hormonotherapy with tamoxifen. The 10-year DFS rate was 90%. Out of 120 patients with T-MBC, only 4 (3.3%) died from this cancer. We showed that none of the population, neither clinical nor microscopic, had a statistically significant influence on the 10-year disease-free survival rate. Our results are similar to others presented in literature. NOWOTWORY J Oncol 2017; 67, 1: 7-13

show abstract

Section: Stage Of Diseasesupporting

confidence: 92%

Section: Clinicopathologic Characteristicsmentioning

confidence: 60%

See 1 more Smart Citation

Typical medullary breast carcinoma: clinical outcomes and treatment results

Stelmach¹,

Ryś²,

Mituś³

et al. 2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…They concluded that histologic subtype was not a significant factor for SN false negative rate, which was 9.4% for 'other subtypes' (not ductal nor lobular) ahead of ductal/lobular carcinoma (7.8%). Wong et al (6) pointed out more specific data, as they described more extensive results on SN feasibility with SN identification rates near 100% in tubular and papillary subtypes and slightly less (92%) in colloid and medullary subtypes.…”

Section: Discussionmentioning

confidence: 99%

Sentinel Node Biopsy in Special Histologic Types of Invasive Breast Cancer

Solá

Recaj

Castellà³

et al. 2016

J Breasth Health

View full text Add to dashboard Cite

IntroductionSentinel node biopsy (SNB) is a minimally invasive technique used to stage the axilla in patients with early breast cancer and is the current gold standard for lobular or ductal breast carcinoma (1-3). However, around 10% of breast tumors belong to other histologic subtypes such as tubular, colloid, medullary, papillary carcinoma, and others. This is a heterogeneous group of malignancies known as special histologic types (SHT) of invasive breast cancer, with variable outcomes, as well as with variable rates of axillary metastases (4, 5).Some authors have advocated that complete axillary dissection (CAD) could be omitted because axillary involvement is uncommon in such tumors. However, the question is whether SNB itself can also be omitted. As the SNB technique keeps improving and consolidating, some authors have shown a higher than expected rate of positive sentinel nodes in this subset (6). This remains an outstanding question for its implication in adjuvant treatment planning. Although SNB morbidity is lower than CAD morbidity, SNB has nevertheless been reported to carry a lymphedema risk of around 10%.Sentinel node biopsy in these unusual subtypes of breast cancer is poorly studied. The series of these patients are short and there are no data on the technical feasibility in this kind of breast cancer.The purpose of this study was to assess the feasibility of sentinel node biopsy in special histologic types of invasive breast cancer. Materials and Methods:Between January 1997 and July 2008, 2253 patients from 6 affiliated hospitals underwent SNB who had early breast cancer and clinically negative axilla. The patients' data were collected in a multicenter database. For lymphatic mapping, all patients received an intralesional dose of radiocolloid Tc-99m (4mCi in 0.4 mL saline), at least two hours before the surgical procedure. SNB was performed by physicians from the same nuclear medicine department in all cases. Results:Of the 2253 patients in the database, the SN identification rate was 94.5% (no radiotracer migration in 123 patients), and positive sentinel node prevalence was 22%. SHT was reported in 144 patients (6.4%) of the whole series. In this subgroup, migration of radiotracer was unsuccessful in 8 patients (identification rate was 94.4%) and SNs were positive in 7.4%. SN positivity prevalence in these tumors was variable across the subtypes. Higher probability of lymphatic spread seemed to be related to tumor invasiveness (20% of positivity in micropapillary, 15% in cribriform subtypes, and 0% in adenoid-cystic). Conclusion:Sentinel node biopsy is feasible in special histologic subtypes of breast carcinoma with a good identification rate. Lower migration rates, however, might be associated with special histologic features (colloid subtype). Complete axillary dissection after a positive sentinel node cannot be omitted in patients with SHT breast cancer because they can be associated with further axillary disease; the reported very low incidence of axillary metastases would justify avoiding...

show abstract

“…A introdução da biópsia de linfonodo sentinela (BLS) permitiu um novo pensamento acerca da investigação do status axilar nos casos de microinvasão, pois este procedimento tem menor morbidade e permite um estadiamento mais preciso usando cortes seriados e estudo imuno-histoquímico do linfonodo sentinela. A taxa de BLS positivo em pacientes com diagnóstico de microinvasão tem se mostrado baixa na totalidade de estudos acerca do assunto [15][16][17][18][19][20][21] . A sobrevida do CMM é igual à sobrevida das pacientes diagnosticadas com CDIS puro.…”

Section: Discussionunclassified

Carcinoma microinvasor de mama: resultados em longo prazo

Gioia¹,

Marinho²,

Murteira³

et al. 2016

Rev. Bras. Mastol. (Impr.)

View full text Add to dashboard Cite

A aparência radiológica das calcificações encontrada nas lesões de CMM (68%) mimetizou os achados vistos no CDIS. Axila positiva foi encontrada em 9,6% dos casos. Após um seguimento médio de oito anos, foi observado um caso de recidiva loco regional e quatro casos de recidiva à distancia. A sobrevida global foi de 95,6% e a sobrevida livre de doença, de 96,5%. Conclusão: Apesar do potencial de metástase nodal no nosso estudo, o CMM possui um bom prognóstico e é associado ao baixo risco de metástase para linfonodos axilares. O conhecimento da clínica e da radiologia de lesões com CDIS poderá alertar ao médico sobre a possibilidade de microinvasão e orientação do manejo adequado para cada paciente. ABSTRACT Objective: Microinvasive breast carcinoma (MBC) is an uncommon breast carcinoma subtype although an increase of screening mammography in recent decades has resulted in a higher incidence of ductal carcinoma in situ (DCIS), as well as invasive carcinomas at early stages. The objective of this research study was to review 115 cases of MBC from Brazilian National Cancer

show abstract

Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes

Cited by 59 publications

References 17 publications

Typical medullary breast carcinoma: clinical outcomes and treatment results

Typical medullary breast carcinoma: clinical outcomes and treatment results

Sentinel Node Biopsy in Special Histologic Types of Invasive Breast Cancer

Carcinoma microinvasor de mama: resultados em longo prazo

Contact Info

Product

Resources

About